Axonics, Inc. AXNX has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia. This cutting-edge ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ ...

Irvine-based upstart Spiro Medical, whose chairman is Axonics founder Raymond Cohen, raised a $67 million Series A funding ...

Raymond Cohen, co-founder of Axonics, can now breathe a sigh of relief. After a long delay tied to a federal probe of the Axonics sale, Boston Scientific Corp. (NYSE: BSX) announced Nov. 15 the ...

Boston Scientific Corporation plans to acquire Axonics, Inc. for $3.7 billion in cash to expand its urology offerings with Axonics' innovative urinary and bowel disorder treatments. Axonics, founded ...

It’s finally over. Medtronic and Boston Scientific’s Axonics longstanding patent battle is finished. The companies settled the legal spat over patent infringements related to sacral neuromodulation ...

Weighted-average shares used to compute basic and diluted net loss per share ...

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics, Inc. after entering into a purchase agreement in January. Axonics, a publicly traded ...

Boston Scientific Corporation BSX recently closed the acquisition of Axonics, Inc., a medical technology company focused on the development and commercialization of differentiated devices to treat ...

Axonics, Inc. (NASDAQ:AXNX) rose 1.5% in after-hours trading after a jury voted in its favor in a patent dispute with Medtronic (MDT). Medtronic (MDT) was seeking $150 million in a patent dispute with ...